Skip to main content
    E

    Evoke Pharma Inc (EVOK)

    Official site

    DRUG MANUFACTURERS - SPECIALTY & GENERIC

    $11.00
    +0.00 (+0.00%)

    Last updated: Dec 17, 2025 at 4:00 PM ET

    Evoke Pharma Inc (EVOK) Financials: Revenue, Profit and Cash Flow

    Updated Nov 10, 2025. Financial statements from company filings, amounts in US dollars.

    Evoke Pharma reported revenue of $10.25M for the fiscal year ended Dec 31, 2024, up 97.8% from the year before. That year, net income was -$5.35M with a net margin of -52.2%, operating cash flow was -$5.46M and free cash flow was -$5.46M. The quarter ended Sep 30, 2025 had revenue of $4.28M and net income of -$1.16M.

    Revenue and Margins

    The operating margin was -50.8% in the fiscal year ended Dec 2024.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2024$10.25M+97.8%96.5%-50.8%-52.2%
    Dec 2023$5.18M+106.5%96.1%-143.4%-150.4%
    Dec 2022$2.51M+55.0%85.2%-310.4%-327.8%
    Dec 2021$1.62M+6929.0%79.7%-503.8%-527.7%
    Dec 2020$23.02KN/A-276.7%-56678.3%-57144.5%
    Dec 2019$0N/AN/AN/AN/A
    Dec 2018$0N/AN/AN/AN/A
    Dec 2017$0N/AN/AN/AN/A
    Dec 2016$0N/AN/AN/AN/A
    Dec 2015$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2015 to Dec 2024

    Income Statement

    In the fiscal year ended Dec 2024, the net loss narrowed from the year before. In the quarter ended Sep 2025, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016Dec 2015
    Revenue$10.25M$5.18M$2.51M$1.62M$23.02K$0$0$0$0$0
    Cost of revenue$356.53K$201.88K$370.39K$328.12K$86.71K$0$0$0$0$0
    Gross profit$9.89M$4.98M$2.14M$1.29M-$63.69K$0$0$0$0$0
    Research and development$16.32K$181.91K$300.79K$590.48K$6.55M$3.42M$4.10M$7.14M$6.95M$8.15M
    Operating income-$5.20M-$7.43M-$7.79M-$8.15M-$13.05M-$7.15M-$8.01M-$11.23M-$10.54M-$11.82M
    Net income-$5.35M-$7.79M-$8.22M-$8.54M-$13.15M-$7.13M-$7.57M-$12.23M-$10.75M-$12.12M
    EBITDA-$5.20M-$7.43M-$7.79M-$8.15M-$13.05M-$7.15M-$7.58MN/A-$10.48M-$11.82M
    Fiscal years ended Dec 2015 to Dec 2024

    Quarterly

    Line itemSep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022
    Revenue$4.28M$3.75M$3.08M$3.31M$2.65M$2.55M$1.74M$1.68M$1.56M$1.13M$810.41K$796.37K
    Gross profit$4.18M$3.58M$3.04M$3.19M$2.55M$2.51M$1.64M$1.62M$1.53M$1.07M$759.82K$606.28K
    Operating income-$1.14M-$1.56M-$1.30M-$1.19M-$1.29M-$1.22M-$1.50M-$1.89M-$1.60M-$1.78M-$2.16M-$1.71M
    Net income-$1.16M-$1.57M-$1.31M-$1.19M-$1.31M-$1.27M-$1.58M-$1.99M-$1.69M-$1.87M-$2.24M-$1.80M
    Last 12 quarters

    Balance Sheet

    As of Dec 2024, cash and equivalents exceeded short-term debt of $5.00M by $8.60M.

    Annual

    Line itemDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016Dec 2015
    Total assets$17.52M$7.07M$11.85M$10.57M$9.43M$6.40M$5.66M$7.94M$9.29M$9.53M
    Current assets$17.24M$6.83M$11.72M$10.56M$9.28M$6.25M$5.65M$7.93M$9.28M$9.52M
    Cash and equivalents$13.60M$4.74M$9.84M$9.14M$8.07M$5.66M$5.32M$7.68M$9.01M$8.69M
    Total liabilities$10.48M$9.65M$7.77M$7.02M$12.65M$2.02M$1.63M$5.78M$5.51M$6.07M
    Short-term debt$5.00M$5.00M$0$12.43K$245.87K$138.54KN/AN/AN/A$146.05K
    Long-term debtN/A$0$5.00M$5.00M$5.00M$0N/A$0$0$4.23M
    Shareholder equity$7.04M-$2.58M$4.08M$3.56M-$3.21M$4.38M$4.03M$2.17M$3.79M$3.46M
    Fiscal years ended Dec 2015 to Dec 2024

    Quarterly

    Line itemSep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022
    Total assets$15.65M$16.06M$16.38M$17.52M$14.15M$12.14M$12.45M$7.07M$7.85M$8.98M$10.04M$11.85M
    Total liabilities$12.29M$11.69M$10.53M$10.48M$9.77M$9.47M$8.96M$9.65M$8.73M$8.44M$7.91M$7.77M
    Cash and equivalents$11.58M$12.06M$12.62M$13.60M$11.34M$9.18M$9.70M$4.74M$5.96M$7.01M$8.21M$9.84M
    Shareholder equity$3.36M$4.37M$5.84M$7.04M$4.39M$2.66M$3.50M-$2.58M-$873.77K$538.37K$2.13M$4.08M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2024.

    Annual

    Line itemDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016Dec 2015
    Operating cash flow-$5.46M-$4.98M-$6.60M-$12.35M-$6.63M-$5.76M-$6.98M-$8.72M-$8.71M-$10.50M
    Capital expenditures$0$3$0$0$0$0$0$0$0$0
    Free cash flow-$5.46M-$4.98M-$6.60M-$12.35M-$6.63M-$5.76M-$6.98M-$8.72M-$8.71M-$10.50M
    Dividends paidN/AN/AN/AN/A$5.10MN/AN/A$0$0$0
    Share repurchases$426.29K$119.30K$0$1.30MN/AN/AN/AN/AN/AN/A
    Financing cash flow$14.32M-$119.30K$7.29M$13.43M$9.04M$6.11M$4.62M$7.39M$9.02M$5.03M
    Fiscal years ended Dec 2015 to Dec 2024

    Quarterly

    Line itemSep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022
    Operating cash flow-$521.96K-$565.02K-$997.51K-$1.24M-$818.70K-$820.62K-$2.58M-$1.11M-$1.04M-$1.21M-$1.63M-$2.51M
    Capital expenditures$2$0$0$2$5$5$4$0$0$0$0$0
    Free cash flow-$521.96K-$565.02K-$997.51K-$1.24M-$818.70K-$820.62K-$2.58M-$1.11M-$1.04M-$1.21M-$1.63M-$2.51M
    Last 12 quarters

    Frequently Asked Questions About EVOK

    What is Evoke Pharma's annual revenue?

    Evoke Pharma reported revenue of $10.25M for the fiscal year ended Dec 31, 2024.

    How fast is Evoke Pharma's revenue growing?

    Revenue was up 97.8% for the fiscal year ended Dec 31, 2024 compared with the year before. The compound annual revenue growth rate over 3 years was 85.0%.

    Is Evoke Pharma profitable?

    No. Evoke Pharma reported net income of -$5.35M for the fiscal year ended Dec 31, 2024, with a net margin of -52.2%.

    How much free cash flow does EVOK generate?

    For the fiscal year ended Dec 31, 2024, operating cash flow of -$5.46M minus capital expenditures of $0 produced free cash flow of -$5.46M.

    How much debt does Evoke Pharma have?

    The balance sheet dated Dec 31, 2024 reported short-term debt of $5.00M and cash and equivalents of $13.60M.